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AaDO~2~

:   arterio‐alveolar oxygen pressure difference

BAL

:   bronchoalveolar lavage

BALF

:   bronchoalveolar lavage fluid

bpm

:   breaths per minute

CpG‐ODN

:   cytosine‐phosphate‐guanosine‐oligodeoxynucleotide

GNP

:   gelatin nanoparticle

HPW

:   highly purified water

IFN

:   interferon

IL

:   interleukin

PaO~2~

:   partial oxygen pressure

RAO

:   recurrent airway obstruction

RU

:   relative unit

TBS

:   tracheobronchial secretion

Th

:   T‐helper cell

TLR‐9

:   toll‐like receptor 9

Tregs

:   T regulatory cells

Recurrent airway obstruction (RAO) is 1 of the most common immune‐mediated allergic conditions in horses in the northern hemisphere.[1](#jvim12524-bib-0001){ref-type="ref"}, [2](#jvim12524-bib-0002){ref-type="ref"}, [3](#jvim12524-bib-0003){ref-type="ref"} RAO could serve as a natural model for allergic asthma in humans and shares many characteristics with this disease.[2](#jvim12524-bib-0002){ref-type="ref"}, [4](#jvim12524-bib-0004){ref-type="ref"} Trigger factors are assumed to be allergens in dusty hay and moldy straw (depending on the geographical location), harmful gases (eg, ammonia, particulate matter from the environment in the stable[5](#jvim12524-bib-0005){ref-type="ref"}) infectious diseases,[1](#jvim12524-bib-0001){ref-type="ref"} and genetic and epigenetic factors.[6](#jvim12524-bib-0006){ref-type="ref"} The underlying pathogenesis presumably is a hypersensitivity immune reaction (types I, III, and IV) resulting in hyperreactivity of the airways to these triggers.[3](#jvim12524-bib-0003){ref-type="ref"}, [7](#jvim12524-bib-0007){ref-type="ref"}, [8](#jvim12524-bib-0008){ref-type="ref"} Clinical variables include cholinergic bronchospasm, hypercrinia and dyscrinia, nasal discharge, coughing, airway neutrophilia, airway remodeling, and edema, resulting in poor performance.[1](#jvim12524-bib-0001){ref-type="ref"}, [8](#jvim12524-bib-0008){ref-type="ref"}, [9](#jvim12524-bib-0009){ref-type="ref"}

Cytosine‐phosphate‐guanosine‐oligodeoxynucleotide (CpG‐ODN) has been identified as a molecule that directs the immune system toward a cell‐mediated Th1 pathway, away from the pro‐allergic humoral Th2 line response, described as a Th2/Th1‐shift.[3](#jvim12524-bib-0003){ref-type="ref"}, [10](#jvim12524-bib-0010){ref-type="ref"}, [11](#jvim12524-bib-0011){ref-type="ref"} Unmethylated CpG‐ODN molecules exist naturally in prokaryotic viral and bacterial DNA and stimulate the mammalian immune system, via the Th1 pathway, against infectious agents.[10](#jvim12524-bib-0010){ref-type="ref"}, [11](#jvim12524-bib-0011){ref-type="ref"} A recognition receptor for CpG‐ODN is the toll‐like‐receptor‐9 (TLR‐9) which has been identified in macrophages, bronchial epithelial cells, capillary endothelial cells, and neutrophil granulocytes in equine lungs.[12](#jvim12524-bib-0012){ref-type="ref"} Drug delivery systems such as lipid[13](#jvim12524-bib-0013){ref-type="ref"} or gelatin nanoparticles (GNPs) have been used to protect CpG‐ODN in vivo against nuclease degeneration.[14](#jvim12524-bib-0014){ref-type="ref"}, [15](#jvim12524-bib-0015){ref-type="ref"} GNPs represents a highly efficient drug delivery system, which also has the advantages of being aerodynamically stable after inhalation, immunologically inert, biodegradable, and biocompatible.[14](#jvim12524-bib-0014){ref-type="ref"}, [15](#jvim12524-bib-0015){ref-type="ref"}, [16](#jvim12524-bib-0016){ref-type="ref"}, [17](#jvim12524-bib-0017){ref-type="ref"}, [18](#jvim12524-bib-0018){ref-type="ref"}, [19](#jvim12524-bib-0019){ref-type="ref"}

As an adjuvant, CpG‐ODN has been successfully used both in a human phase I and IIa in vivo asthma study with the house dust mite allergen as well as in a study of atopic dogs with specific allergens as an allergen‐specific immunotherapy.[20](#jvim12524-bib-0020){ref-type="ref"}, [21](#jvim12524-bib-0021){ref-type="ref"} CpG‐ODN also has been applied as an adjuvant in in vitro and in vivo vaccination studies.[22](#jvim12524-bib-0022){ref-type="ref"}, [23](#jvim12524-bib-0023){ref-type="ref"}, [24](#jvim12524-bib-0024){ref-type="ref"}, [25](#jvim12524-bib-0025){ref-type="ref"} Furthermore, it has been used as an adjuvant in an equine influenza vaccine in horses[23](#jvim12524-bib-0023){ref-type="ref"} and in combination with a *Rhodococcus equi* vaccine.[22](#jvim12524-bib-0022){ref-type="ref"}

A preliminary study of the inhalation of GNP‐bound CpG‐ODN as the only active agent showed promising clinical results in a small group of RAO‐affected horses and healthy horses, in contrast to previously used adjuvants.[26](#jvim12524-bib-0026){ref-type="ref"} No local or systemic inflammatory reactions were observed.[26](#jvim12524-bib-0026){ref-type="ref"} The efficiency of this novel formulation was demonstrated by improvement in arterial blood gases, breathing rate, amount of intratracheal mucus accumulation, viscosity, and airway neutrophilia in RAO‐affected horses.[26](#jvim12524-bib-0026){ref-type="ref"}

The goal of this exploratory study was (i) to verify the results of the previous pilot study using a larger subject group and with a placebo control, and (ii) to investigate a possible sustained response in the weeks after treatment in the field. The main goals of the field study were the evaluation of (i) a clinically relevant improvement in breathing pattern, respiratory rate, arterial blood gases, and AaDO~2~, as well as (ii) a clinically relevant percentage decrease in neutrophilic granulocytes in the airways, as well as decrease in intrapleural pressure, nasal discharge, amount of secretion, and viscosity of secretions in the airways in comparison to the initial examination and the control group after 5 inhalations of nanoparticle‐bound CpG‐ODN. Additionally, the duration of the effectiveness of the nanoparticle immunotherapy, as well as the tolerability of the formulation and the absence of adverse effects, were examined.

The first hypothesis of this study was that placebo administration would show no or very limited improvement in the monitored variables in comparison to the experimental administration. The secondary hypothesis was that the nanoparticle‐bound CpG‐ODN immunotherapy would produce no local or systemic adverse reactions.

Methods {#jvim12524-sec-0007}
=======

Study Design {#jvim12524-sec-0008}
------------

This study was performed as a randomized, double‐blinded, and placebo‐controlled clinical trial. The subjects were 24 horses with a history of chronic RAO (mean age, 16.1 years ± 5.1; 5 mares, 17 geldings, and 2 stallions; mean weight, 519.4 kg ± 129.7). The following inclusion criteria were applied: increased respiratory rate at rest (\>16/min), increased abdominal breathing("heaves"), abnormal auscultatory findings at rest, increased numbers of neutrophils in the airways (\>25%), decreased partial pressure of arterial oxygen (\<90 mmHg), increased intrapleural pressure (\>15 cmH~2~O), and clinical signs induced by contact with straw and hay, as well as reversibility of clinical signs with avoidance of allergens and sustained time on pasture[1](#jvim12524-bib-0001){ref-type="ref"}, [27](#jvim12524-bib-0027){ref-type="ref"}. All of the horses were kept in their usual environment during the entire study (April through July) and were examined without modifying their stabling (open bar stall, n = 7; box with sawdust, n = 10; straw, n = 7), feeding (dry hay, n = 21; soaked hay, n = 3) or activity. For at least 2 months before and during the study, the horses received neither supplement medication nor improvements to their stabling or management. This trial was performed as an exploratory field study. In the placebo group, 25% of the horses were kept in open stables and 75% in box stalls (bedding material was shavings and sawdust in 38% and straw in 38%). All of the horses in the placebo group were fed dry hay before and during the study. In the active treatment group, 31% of the horses were kept in open stables and 69% in stalls. In 81% of the cases, the horses were fed dry hay and 19% were fed wet hay (only 3 of the horses kept in stalls received wet hay).

Two different investigators performed the inhalation therapy (BL) and clinical examinations (JK). In addition, the placebo and experimental formulations could not be differentiated visually. Neither the horse owners nor the examiners knew if the horse had received the placebo or active treatment.

The patients were randomly assigned to 2 groups. After 8 horses were selected for the placebo group, the remaining horses were assigned to the experimental treatment group. This randomization took place after all of the patients were selected for the study. The placebo group (n = 8) received inhalations with highly purified water (HPW) and GNP, and the experimental treatment group (n = 16) received inhalations with GNP‐bound CpG‐ODN.[1](#jvim12524-note-0001){ref-type="fn"} ^,^ [26](#jvim12524-bib-0026){ref-type="ref"} The inhalation regimen, corresponding to the procedure in the previous study, was performed with the Equine Haler[2](#jvim12524-note-0002){ref-type="fn"} and the AeroNeb Go mesh vibrator.[3](#jvim12524-note-0003){ref-type="fn"} ^,^ [26](#jvim12524-bib-0026){ref-type="ref"} In total, each horse received 5 inhalations, each separated by 2 days. The horses were examined 3 times: at the beginning, ie, before the first administration of experimental treatment or placebo; (I) to determine each horsis clinical status; directly after the final inhalation (II); and 4 weeks after the final inhalation (III), to provide insight on the duration of effectiveness. To this end, each examination included clinical examinations, endoscopy, cytology, and serum biochemistry, as well as measurement of intrapleural pressure.

The nanoparticles were produced and charged with CpG‐ODN according to the protocol of a previous study[26](#jvim12524-bib-0026){ref-type="ref"}. The study was approved by the regional legal agency for animal testing of the State Government of Bavaria, Germany (No. 55.2‐1‐54‐2531‐31‐10).

Clinical Examination and Scoring {#jvim12524-sec-0009}
--------------------------------

The clinical variables were evaluated according to established and standardized scoring systems when possible. The following variables were examined: breathing rate per minute (bpm), breathing type (relative units \[RU\] in the range of 0--3, where 0 = no or little movement in the ventral flank and 3 = obvious abdominal lift and heave line),[28](#jvim12524-bib-0028){ref-type="ref"} nasal discharge (RU in the range of 0--2, where 0 = none, 1 = mild and 2 = moderate discharge), auscultation of the lungs and trachea (in the range of RU 0 to 4, where 0 = physiological, 1 = mild, 2 = moderate, 3 = severe, 4 = wheeze or rhonchus),[1](#jvim12524-bib-0001){ref-type="ref"}, [26](#jvim12524-bib-0026){ref-type="ref"}, [27](#jvim12524-bib-0027){ref-type="ref"} and arterial blood gas parameters.[29](#jvim12524-bib-0029){ref-type="ref"} The latter consisted of partial oxygen pressure (paO~2~)~,~ with a normal reference value of 100 ± 5 mmHg, and carbon dioxide pressure (paCO~2~), with a normal reference value of 40 ± 5 mmHg). Arterial blood gases were measured by an IRMA blood analysis system.[4](#jvim12524-note-0004){ref-type="fn"} The arterio‐alveolar‐oxygen‐pressure difference (AaDO~2~) was calculated from the actual air pressure and measured arterial blood gases (AaDO~2~ = \[actual air pressure − 47 mmHg\] × 0.2095 − PaCO~2~ − PaO~2~).[29](#jvim12524-bib-0029){ref-type="ref"} In addition, an endoscopic examination and a quantification of secretion (grade 0--5, where 0 = none, clean, singular tracheobronchial secretion \[TBS\] to 5 = extreme, profuse amounts)[30](#jvim12524-bib-0030){ref-type="ref"} and viscosity (where grade 1 = fluid to 5 = viscous)[30](#jvim12524-bib-0030){ref-type="ref"} of the TBS was performed. Cytological examinations of the TBS samples were performed to determine the percentage of neutrophils in the total cell count after staining with Diff‐Quick solution.[5](#jvim12524-note-0005){ref-type="fn"} Indirect measurement of the maximum intrapleural pressure differences (Δ Ppl max) was performed by a Venti‐Graph[6](#jvim12524-note-0006){ref-type="fn"} via esophageal probe.[31](#jvim12524-bib-0031){ref-type="ref"}

To test the tolerability of the formulation and its application, the horses were regularly monitored for the signs of increased nasal discharge, coughing, bronchospasm, increased respiratory rate, endoscopically visible local hyperemia of the mucous membranes, follicular hyperplasia, and decreased partial oxygen pressure. Furthermore, body temperature, differential blood cell count, and plasma fibrinogen concentration were measured to evaluate the systemic effects of treatment.

Statistical Analysis {#jvim12524-sec-0010}
--------------------

The comparison of patients within each group (placebo and experimental treatment) for the preliminary examination before treatment was carried out for normally distributed data (based on Shapiro‐Wilk analysis) with the paired Student\'s *t*‐test for parametric data. For non‐parametric data, the Wilcoxon matched pairs signed rank test was used for paired values (comparison within the groups) and the Mann‐Whitney test was used for unpaired data (comparison between the groups). All statistical analyses were performed using GraphPad Prism 5 software.[7](#jvim12524-note-0007){ref-type="fn"} Results with a calculated value of *P *\<* *0.05 were considered statistically significant (displayed as \*; *P *\<* *0.01 as \*\*; *P *\<* *0.001 as \*\*\*) and were reported as the mean ± S.D. The 95% confidence intervals (CI) were calculated and presented in brackets. Effect size (Cohen\'s *d*) was assessed for each piece of data (to estimate clinical relevance: mild, *d *=* *0.2--0.3; moderate, *d *=* *0.5; large, *d *\>* *0.8). The calculation of the effect size was performed using the EffectSize Calculator.[8](#jvim12524-note-0008){ref-type="fn"} ,[29](#jvim12524-bib-0029){ref-type="ref"}

Results {#jvim12524-sec-0011}
=======

Safety {#jvim12524-sec-0012}
------

Throughout the whole study period, no local or systemic inflammatory reactions or adverse effects were observed after inhalation treatment with GNP‐bound CpG‐ODN. Specifically, no clinically detectable increased nasal discharge, coughing, bronchospasm, increased breathing rate, endoscopically visible local hyperemia, follicular hyperplasia, or decreased arterial blood gas pressure were observed. In addition, no increase in rectal temperature, peripheral blood absolute and differential leukocyte counts or plasma fibrinogen concentrations were detected.

Respiratory Rate {#jvim12524-sec-0013}
----------------

No clinically or statistically significant decrease in respiratory rate was observed, either directly after placebo inhalation or after 4 weeks (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). After treatment, no statistically significant improvement (*P *=* *0.0856; clinical relevance, *d* = 0.6; CI:−0.1 to 1.3) could be detected immediately after treatment (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}) or after 4 weeks (clinical relevance, *d* = 0.3; CI: −0.4 to 1.0). However, a statistically significant difference (*P *=* *0.0247) in the percentage decrease in respiratory rate was detected between the placebo and treatment groups between the first and last examination (I--III) (Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

###### 

Clinical, endoscopic, cytological, and biochemical parameters: Results of breathing rate and type, lung auscultation, intrapleural pressure measurement, oxygen partial pressure, AaDO~2~, neutrophil percentage of TBS, nasal discharge, endoscopic quantification of secretion and viscosity depicted before (I), after 5 inhalations (II), and 4 weeks post‐treatment (III) with placebo (n = 8 RAO‐affected horses) versus treatment administration (n = 16 RAO‐affected horses) (RU = relative units, scoring system; mean ± SD)

                    Breathing rate \[1/min\]   Breathing type \[RU\]   Auscultation \[RU\]   Interpleural pressure \[cmH~2~0\]                                                                                           
  ----------------- -------------------------- ----------------------- --------------------- ----------------------------------- ----------- ----------- ----------- ----------- ----------- ------------- ------------- -------------
  Placebo (n = 8)   21.0 ± 5.1                 20.0 ± 4.7              23.1 ± 10.1           1.4 ± 1.1                           1.5 ± 1.1   1.3 ± 1.0   2.1 ± 1.2   2.1 ± 1.2   2.0 ± 1.2   26.8 ± 29.4   25.5 ± 19.8   28.0 ± 36.4
  Verum (n = 16)    21.6 ± 5.7                 18.3 ± 4.6              19.5 ± 6.6            2.4 ± 0.9                           1.1 ± 0.7   1.2 ± 0.9   2.8 ± 1.0   1.2 ± 0.7   1.5 ± 0.8   26.7 ± 22.5   9.8 ± 8.5     30.8 ± 33.6

                    Oxygen partial pressure \[mmHg\]   AaDO2 \[mmHg\]   Neutrophils \[%\]                                                                         
  ----------------- ---------------------------------- ---------------- ------------------- ------------- ------------- ------------- ------------- ------------- -------------
  Placebo (n = 8)   79.6 ± 11.1                        76.1 ± 8.0       77.9 ± 13.6         23.6 ± 12.6   27.0 ± 7.2    26.5 ± 11.6   68.0 ± 18.7   67.4 ± 19.6   73.2 ± 12.3
  Verum (n = 16)    71.4 ± 15.9                        85.9 ± 13.1      75.1 ± 17.1         30.6 ± 11.5   19.2 ± 11.8   25.7 ± 13.6   78.9 ± 17.7   72.9 ± 18.1   70.2 ± 24.4

                    Nasal discharge \[RU\]   Quantification of secretion \[RU\]   Viscosity \[RU\]                                                               
  ----------------- ------------------------ ------------------------------------ ------------------ ----------- ----------- ----------- ----------- ----------- -----------
  Placebo (n = 8)   0.9 ± 0.6                0.9 ± 0.6                            0.9 ± 0.7          1.8 ± 1.2   1.6 ± 0.9   1.7 ± 0.8   1.6 ± 1.3   1.5 ± 1.1   1.5 ± 0.8
  Verum (n = 16)    1.4 ± 0.6                0.5 ± 0.6                            0.7 ± 0.5          3.3 ± 1.1   1.4 ± 1.1   1.9 ± 0.8   3.1 ± 1.2   1.7 ± 0.9   1.9 ± 0.8
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![Relative reduction or increase of clinical, endoscopic, cytological, and biochemical parameters: Relative decrease or increase of breathing rate and pattern (calculated value of *P *\< 0.05 displayed as \*; *P *\< 0.01 as \*\*; *P *\< 0.001 as \*\*\*; *P *\< 0.0001 as \*\*\*\*), lung auscultation, intrapleural pressure measurement, oxygen partial pressure, AaDO ~2~, percentage of neutrophils in TBS, nasal discharge, endoscopic quantification of secretion and viscosity depicted in percent between first and second (I--II) and first and third (I--III) examinations and in comparison between placebo (white bars, n = 8 RAO‐affected horses) and treatment group (gray bars, n = 16 RAO‐affected horses; mean ± SD).](JVIM-29-286-g001){#jvim12524-fig-0001}

Breathing Pattern {#jvim12524-sec-0014}
-----------------

The placebo group showed no statistically significant improvement in breathing pattern after the inhalation regimen (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). However, a statistically significant (*P *=* *0.0007; *d* = 1.6; CI: 0.8--2.4) improvement in breathing type was detected in the treatment group after 5 inhalations (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}), and a reduction of one grade from the initial status was observed after 4 weeks (*P *=* *0.005; clinical relevance, *d* = 1.3; CI: 0.5--2.1) (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant difference was detected between the placebo and experimental treatment groups in percentage decrease in breathing pattern between the first and second examination (I--II; *P *=* *0.0008) as well as between the first and third examination (I--III, *P *=* *0.0051; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Lung Auscultation {#jvim12524-sec-0015}
-----------------

No statistically significant improvement in auscultation was observed after the inhalation regimen in the placebo group (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). By contrast, a significant (*P *=* *0.0004; clinical relevance, *d* = 1.9; CI: 1.0--2.6) improvement in auscultation was detected in the treatment group after 5 inhalations. In the treatment group, a mean decrease of \>1.5 grades was observed. A significant decrease in duration of efficacy (*P *=* *0.0018; clinical relevance, *d* = 1.4; CI: 0.6--2.2) also was observed in horses treated with GNP‐bound CpG after 4 weeks (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant difference was observed between the placebo and treatment groups when comparing percentage improvement in auscultation between the first and second examination (I--II; *P *\<* *0.0001) and between the first and third examination (I--III; *P *=* *0.0015; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Intrapleural Pressure {#jvim12524-sec-0016}
---------------------

No statistically significant decrease in intrapleural pressure after inhalation treatment was observed in the placebo group (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). The treatment group showed an average improvement in intrapleural pressure of 16 cmH~2~O (clinical relevance, *d* = 1.0; CI: 0.2--1.7) immediately after inhalation administration, but this difference lacked statistical significance (*P *=* *0.1269; Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}) because of large individual variations. The clinical effect observed did not persist 4 weeks after treatment. No statistically significant differences between placebo and treatment group were observed when comparing percentage intrapleural pressure improvement (Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Partial Oxygen Pressure (pO~2~) {#jvim12524-sec-0017}
-------------------------------

The placebo group failed to show any statistically significant improvement in arterial blood gas results post inhalation (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). However, pO~2~ increased on average by approximately 14 mmHg in the treatment group (from 71.4 mmHg ± 15.9 to 85.9 mmHg ± 13.1) after 5 inhalations (*P *=* *0.0006; clinical relevance, *d* = 1.0; CI: 0.2--1.7) (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}). A persistent effect over 4 weeks was not observed in the treatment group (*P *=* *0.1523). A statistically significant difference was observed between the placebo and treatment groups when comparing the percentage increase of partial oxygen pressure between the first and the second examination (I--II; *P *=* *0.0228; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Arterio‐alveolar Oxygen Pressure Difference (AaDO~2~) {#jvim12524-sec-0018}
-----------------------------------------------------

The placebo group showed an increase in AaDO~2~ after inhalation of HPW and GNP (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). By contrast, a decrease of 11 mmHg of AaDO~2~ (*P *=* *0.0021; clinical relevance, *d* = 1.0; CI: 0.2--1.7) was observed in the treatment group immediately after the inhalation regime, with a statistically significant persistent effect 4 weeks post‐treatment (*P *=* *0.022, clinical relevance, *d* = 0.4; CI: −0.3 to 1.1; Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant difference also was detected between the placebo and treatment groups when comparing the percentage decrease of AaDO~2~ between the first and the second examinations (I--II; *P *=* *0.0174; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Neutrophil Percentage {#jvim12524-sec-0019}
---------------------

A statistically significant decrease in the neutrophil percentage in TBS was not observed in the placebo group (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). After 4 weeks without treatment, a mild increase in neutrophil percentage then was detected in the placebo group (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). However, in the treatment group, a statistically significant decrease (*P *=* *0.015, clinical relevance, *d* = 0.3; CI: −0.4 to 1.0) was observed after 5 inhalations (from 78.9 ± 17.7% to 72.9 ± 18.1%). Four weeks post‐treatment, no statistically significant effect (*P *=* *0.0975, clinical relevance, *d* = 0.4; CI: −0.3 to 1.1) was observed (to 70.2 ± 24.4%) because of greater SD (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). No statistically significant difference between the placebo and treatment groups comparing the decrease of neutrophil percentage was observed (I--II examination, *P *=* *0.1670; I--III examination, *P *=* *0.0897; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Nasal Discharge {#jvim12524-sec-0020}
---------------

The placebo group showed no statistically significant improvement in nasal discharge after the inhalation regimen with HPW and GNP (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). By contrast, within the treatment group, a statistically significant decrease (*P *=* *0.0012; clinical relevance, *d* = 1.5; CI: 0.7--2.2) after 5 inhalations was observed (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). This effect persisted four weeks post‐treatment (*P *=* *0.0048; clinical relevance, *d* = 1.3; CI: 0.5--2.0; Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant difference was detected between the placebo and experimental treatment groups comparing the percentage decrease in nasal discharge between the first and second examinations (I--II; *P *=* *0.0013) as well as between the first and third examinations (I--III; *P *=* *0.0135; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Quantity of Secretion {#jvim12524-sec-0021}
---------------------

After the inhalation regimen with placebo, no statistically significant decrease in the amount of mucus was observed on tracheal endoscopy (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). By contrast, a statistically significant decrease (*P *=* *0.0007; clinical relevance, *d* = 1.7; CI: 0.9--2.5) of 1.9 RU in secretion amount was observed in the horses treated with the experimental treatment (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}). A persistent effect 4 weeks post‐treatment was detected in the treatment group with a decrease of 1.5 RU after 4 weeks (*P *=* *0.0036; clinical relevance, *d* = 1.5; CI: 0.6--2.2; Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant difference was detected between placebo and treatment groups when comparing the percent decrease in quantity of secretion between the first and the second examinations (I--II; *P *=* *0.0003) as well as between the first and the third examinations (I--III; *P *=* *0.0038; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Viscosity of Secretion {#jvim12524-sec-0022}
----------------------

No statistically significant decrease in viscosity of the TBS was observed in the placebo group (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). However, the treatment group showed a statistically significant decrease in TBS viscosity of 1.4 RU (*P *=* *0.0014; clinical relevance, *d* = 1.3; CI: 0.5--2.1) after the inhalation regimen (Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant persistent effect was detected in the treatment group (*P *=* *0.0029; clinical relevance, *d* = 1.2; CI: 0.4--1.9; Table [1](#jvim12524-tbl-0001){ref-type="table-wrap"}, Fig [1](#jvim12524-fig-0001){ref-type="fig"}). A statistically significant difference was detected between the placebo and treatment groups when comparing percentage decrease in secretion viscosity between the first and the second examinations (I--II; *P *=* *0.0014) as well as between the first and the third examinations (I--III; *P *=* *0.0065; Fig [1](#jvim12524-fig-0001){ref-type="fig"}).

Discussion {#jvim12524-sec-0023}
==========

To the best of our knowledge, this study represents the first attempt at nanoparticle‐based inhalation immunotherapy for horses. Clinical examination, endoscopy, cytology and biochemical variables were evaluated before treatment to determine the pre‐treatment health status of each horse, as well as immediately after 5 inhalations (10 days after the primary examination), and 4 weeks after the last treatment to determine the duration of efficacy. For at least 2 months before and during the course of the field study, the horses received no supplement medication or any modifications to their stabling or management. The patients were treated under their normal stabling conditions and individual exposure to allergens.

The method of inhalation was chosen as a local, topical administration of immunotherapy for the lungs, and proved to be both practical and appropriate. The inhalation system used (ie, a combination of "Equine Haler" and "Aeroneb go") was already proven in a previous study[26](#jvim12524-bib-0026){ref-type="ref"} to be a practical, simple and well‐tolerated system. Its respiratory droplet size,[19](#jvim12524-bib-0019){ref-type="ref"} quiet nebulization,[26](#jvim12524-bib-0026){ref-type="ref"} and short inhalation time[26](#jvim12524-bib-0026){ref-type="ref"} proved to be well adapted for use.

Gelatin nanoparticles have been proven to be immunologically inert, aerodynamically stable, biodegradable, and well tolerated drug delivery systems. Their particular relevance lies in their stabilization and protection of the chimeric backbone[26](#jvim12524-bib-0026){ref-type="ref"} of the Class A CpG‐ODN by steric shielding, as opposed to DNase;[15](#jvim12524-bib-0015){ref-type="ref"} in their selective targeting of the TLR‐9 positive target cells; and in the resulting increased effectiveness of the CpG‐ODN.[15](#jvim12524-bib-0015){ref-type="ref"}, [32](#jvim12524-bib-0032){ref-type="ref"} These aspects, as well as the fact that GNPs are used in (potentially) food‐producing animals, render these nanoparticles of a great importance for a potential application in humans with allergic asthma. The inhalation regimen, with each inhalation session given every 2 days, was selected because of the known maximum 48‐hour in vivo stability of the ODN.[33](#jvim12524-bib-0033){ref-type="ref"}

Within the framework of the study design, the placebo group was intentionally restricted to 8 horses. This decision was made based on ethical considerations regarding the animals' well‐being, the expected efficacy of treatment and the added value of information, as well as the decrease of animal suffering because of the severity of the disease. Because of the smaller number of horses in the placebo group, one cannot expect exactly identical output values, because of the random distribution of data. The effect size (Cohen\'s *d*,*d* \> 0.8 for high clinical relevance) and the 95% CI were calculated in addition to the significance levels, in order to better assess the clinical relevance of the results presented in this study.[34](#jvim12524-bib-0034){ref-type="ref"}

To ensure a safe application of the formulation, possible local and systemic inflammatory reactions or adverse effects were documented, with the help of a modified scoring system from the Veterinary Co‐operative oncology Group\'s Common Criteria of Adverse Events (VCOG‐CTCAE) V1.0.[35](#jvim12524-bib-0035){ref-type="ref"} In accordance with a previous study, no signs of local or systemic inflammatory reactions (including the measurement of plasma fibrinogen concentrations and a differential blood count) or any other adverse effects were observed from the GNP‐bound CpG inhalation treatment. Thus, the second goal of this field study (verification of treatment safety) could be completely satisfied.

As it has already been shown in vitro using equine BAL cells and in vivo*,* GNP‐bound CpG treatment stimulates upregulation of IL‐10.[26](#jvim12524-bib-0026){ref-type="ref"}, [32](#jvim12524-bib-0032){ref-type="ref"}, [35](#jvim12524-bib-0035){ref-type="ref"} This cytokine, which among others is formed from Treg cells, has a regulatory effect on excessive pro‐inflammatory Th1 and pro‐allergic Th2 immune responses, as they occur in the lungs of RAO horses to various degrees.[8](#jvim12524-bib-0008){ref-type="ref"} The anti‐inflammatory and anti‐allergic effect of this immunotherapy, through the activation of TLR‐9 receptors in the lungs, will, according to our hypothesis, stimulate Treg cells to regulate and restore the Th1/Th2 balance that is disturbed in RAO.

The most important effect of the nanoparticle inhalation immunotherapy was the decrease in secretion quantity (ie, nasal discharge and endoscopic findings) as well as the auscultation findings, breathing type and the supply of oxygen to the lungs. Not only was a significant improvement shown in all of these variables after 5 inhalations but also a sustained effect was documented after 4 weeks without supplement treatment or modifications to management conditions. This finding must be particularly emphasized, because the horses in the study were not held in optimal conditions and had constant contact with hay. The clinical relevance of the specific effects also could be classified as very high (*d* \> 0.8).

Whether the immunotherapy has a particularly pronounced effect on the mucus‐producing goblet cells can only be surmised from these results. In mouse models, it is clear that Th2‐mediated immunopathogenesis can be modulated and positively influenced by use of immunostimulatory DNA.[11](#jvim12524-bib-0011){ref-type="ref"}, [15](#jvim12524-bib-0015){ref-type="ref"} The neutrophils, however, showed a comparatively small decrease, which among other things could be explained by sustained exposure to allergens. Through repeated inhalations (ie, booster doses), as was already indicated in our previous pilot study,[26](#jvim12524-bib-0026){ref-type="ref"}, [35](#jvim12524-bib-0035){ref-type="ref"} and perhaps through a modified dosage (ie, dose‐response study), this effect potentially could be strengthened. The previous study also showed an average 30% increase in reduction of neutrophil granulocytes after 5 inhalations[26](#jvim12524-bib-0026){ref-type="ref"}, [35](#jvim12524-bib-0035){ref-type="ref"} during the winter treatment, during which management conditions were optimized.

The improvement of partial oxygen pressure at rest, as well as intrapleural pressure, indicates improved ventilation in the lungs. This also was reflected in the considerably improved breathing pattern and the decrease in active respiratory effort. The cause is most likely the decrease in secretion, as well as a decrease in cholinergic bronchospasm.

In other studies in which CpGs were deployed, for example in a study on asthma in humans,[20](#jvim12524-bib-0020){ref-type="ref"} and a study on dogs with atopic dermatitis,[21](#jvim12524-bib-0021){ref-type="ref"} CpGs were used as adjuvants for an allergen‐specific immunotherapy or as vaccine adjuvants for increased effectiveness of the human hepatitis B[11](#jvim12524-bib-0011){ref-type="ref"} and the equine influenza and *Rhodococcus equi* vaccines.[22](#jvim12524-bib-0022){ref-type="ref"}, [23](#jvim12524-bib-0023){ref-type="ref"}, [24](#jvim12524-bib-0024){ref-type="ref"}, [25](#jvim12524-bib-0025){ref-type="ref"} In these studies, the CpGs induced a strong Th1 cell‐mediated and humoral immune response.[11](#jvim12524-bib-0011){ref-type="ref"} However, they have never been deployed previously as an immuno‐modulatory monotherapy, by inhalation or bound to nanoparticles. As such, this study represents the first inhalation nanoparticle immunotherapy of its kind and is a novel treatment concept for horses. Its use in allergic asthma in humans could therefore also be considered.

The advantage of this immunotherapy lies in stimulation independent of allergens, as opposed to classic hyposensitization. Furthermore, this therapeutic concept works at the immunologic level and helps stabilize the Th1/Th2 balance, which can be of clinical relevance for other allergic and inflammatory diseases. This therapeutic concept opens new possibilities beyond the usual purely symptomatic treatment concepts with cortisone and bronchodilators, or the often unfeasible avoidance of allergen contact. All of the patients included in this study were kept and examined in their normal management conditions, without modifying the usual bedding, feed (hay), or the use of the horse. The goal was to test the effectiveness of the inhalative CpG treatment under individual natural environmental conditions.

The relatively small number of inhalations and the persistent effect over at least a month must be emphasized. Altogether, a significant improvement was observed in the treatment group after 5 inhalations, with a persistent effect over 4 weeks in 70% of the clinical, endoscopic and cytological variables. Thus, an important goal of the study, the verification of the clinical efficacy of the concept (Phase IIa), was fulfilled. Upon review of the examinations, the placebo application, as expected, showed no improvement whatsoever in the variables tested.

Few inhalation treatments have produced a substantial and sustained improvement of allergic and inflammatory clinical, endoscopic, cytological, and biochemical variables. The results of the present field study completely satisfied the questions posed and furthermore indicated a persistent effect in many of the variables tested. This therapeutic approach introduces new perspectives beyond symptomatic treatment methods, and therefore can serve as a model for asthma therapy in humans.
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